Clarivate Plc
Moat Score — Clarivate Plc
Total Moat Score
16 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Clarivate's core data assets — Web of Science citation records, Derwent patent intelligence, Cortellis life sciences data — represent decades of curation and validation work that would take a competitor years and enormous cost to reproduce. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Clarivate is not a low-cost operator; its recent margin-focused restructuring and elevated debt from past acquisitions suggest cost structure pressure rather than a structural cost advantage over competitors. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | A subscription model with renewal rates exceeding 90% indicates customers accept ongoing price increases rather than churn, reflecting real pricing power built on embedded, mission-critical data and workflow tools. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 1 / 5 | Products like Web of Science become modestly more valuable as more institutions contribute citation and publication data into the ecosystem, but this is a mild data effect rather than a strong multi-sided network effect. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 4 / 5 | Once a university, law firm, or pharmaceutical company builds research, IP, or drug-development workflows around Clarivate's databases and software, migrating to a competitor requires re-training staff and re-validating years of historical data, which renewal rates above 90% suggest customers rarely attempt. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | Building and maintaining comprehensive, validated datasets across citation research, patents, and drug development requires enormous fixed investment, which limits the number of competitors able to match Clarivate's breadth across all three of its core markets simultaneously. |